About Robert J. Davis, PharmD:
Robert (Bob) Davis is Vice President, Clinical Operations of Lumos Pharma. Dr. Davis has over 30 years of Drug Development experience and also has extensive regulatory experience having interactions with the FDA, EU and Koseisho in Japan. He served as Chief Operating Officer/Chief Development Officer of ResearchPoint Global from 2004 – 2014. Dr. Davis served as Executive Vice President of Sensus Drug Development Corporation from 1997 to 2001 and was instrumental in the successful registration of Somavert ®, a growth hormone receptor agonist, in the U.S., Europe and Japan.
In addition to Somavert ®, Dr. Davis has been involved in several successfully marketed products including Epogen®, Zithromax® and Salagen®. In 1995, Dr. Davis joined BRI International, Inc. (now Quintiles) as Vice President of Project Management, before becoming President of U.S. Development Services. From 1990 to 1994, he served with Pharmaco (now PPD), as Vice President of Anti-Infective Drug Development, and directed North American operations for compounds in Phase II through IV clinical trials. In 1988, Dr. Davis joined G. D. Searle and served as its Director of Scientific Affairs and led the development of several compounds. In 1984, he joined Warner Lambert/Parke-Davis and served as its Senior Clinical Scientist for Anti-Infectives, eventually becoming Acting Therapeutic Head for Anti-Infectives.
He started his career at University Hospitals of Cleveland. He has filed INDs, NDAs, MAAs and requests for orphan designation, and was part of the team to submit the first electronic NDA to the Division of Endocrinology within the FDA. While at Searle he participated in a group chosen to work with the FDA to write the initial guidelines for developing anti-infective drugs in the United States. He was on Faculty at the University of Maryland and the Baltimore Veterans Medical Center where he first became involved in clinical trials. Dr. Davis received his Doctor of Pharmacy from the University of Maryland in 1978.